The Centers for Medicare & Medicaid Services (CMS) recently selected 15 Medicare-covered drugs for the third cycle of Medicare drug price negotiation, known as IPAY 2028, under the Inflation Reduction Act (IRA).

BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide), a widely used single-tablet HIV treatment regimen, is one of the selected drugs.

This fact sheet provides information and considerations on these negotiations.